These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 34593018

  • 1. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
    Akbari R, Behdarvand T, Afarin R, Yaghooti H, Jalali MT, Mohammadtaghvaei N.
    BMC Pharmacol Toxicol; 2021 Oct 01; 22(1):53. PubMed ID: 34593018
    [Abstract] [Full Text] [Related]

  • 2. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
    Jain MR, Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, Ranvir R, Kadam S, Patel H, Swain P, Roy SS, Das N, Karmakar E, Wahli W, Patel PR.
    Liver Int; 2018 Jun 01; 38(6):1084-1094. PubMed ID: 29164820
    [Abstract] [Full Text] [Related]

  • 3. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, Bedossa P, Sanyal AJ.
    Sci Rep; 2020 Jun 09; 10(1):9330. PubMed ID: 32518275
    [Abstract] [Full Text] [Related]

  • 4. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
    Abd El-Haleim EA, Bahgat AK, Saleh S.
    Eur J Pharmacol; 2016 Feb 15; 773():59-70. PubMed ID: 26825546
    [Abstract] [Full Text] [Related]

  • 5. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N.
    Hepatology; 2021 Oct 15; 74(4):1809-1824. PubMed ID: 33811367
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A.
    Cardiovasc Diabetol; 2019 Jun 17; 18(1):80. PubMed ID: 31208414
    [Abstract] [Full Text] [Related]

  • 11. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y, Cui Y, Wang XL, Shang X, Qi ZG, Xue J, Zhao X, Deng M, Xie ML.
    Cytokine; 2015 Sep 17; 75(1):127-35. PubMed ID: 26194065
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway.
    Makled MN, El-Kashef DH.
    Life Sci; 2020 Jul 15; 253():117729. PubMed ID: 32348836
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Bandyopadhyay S, Samajdar SS, Das S.
    Clin Res Hepatol Gastroenterol; 2023 Aug 15; 47(7):102174. PubMed ID: 37380128
    [Abstract] [Full Text] [Related]

  • 17. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
    Joshi SR.
    Expert Opin Pharmacother; 2015 Mar 15; 16(4):597-606. PubMed ID: 25674933
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.